Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Medicines licensing

Cangrelor approved for use in the United States

Cangrelor has been approved for use in adult patients undergoing percutaneous coronary intervention (PCI) in the United States, following a decision by the US Food and Drug Administration (FDA).

The drug, known as Kengreal in the United States and as Kengrexal in Europe, is an intravenous antiplatelet agent that prevents clots forming and reduces the risk of serious clotting complications – including heart attack and stent thrombosis – in this group of patients.

The decision by the FDA will provide a new treatment option for the estimated 500,000 patients in the United States who undergo PCI every year.

The FDA considered data from a clinical trial of 10,000 patients, in which the drug reduced the occurrence of heart attack or the need for further coronary procedures when compared with another antiplatelet medicine clopidogrel (Plavix). The trial also showed that one in every 170 patients given cangrelor had a serous bleed compared with one in every 275 clopidogrel patients.

The FDA decision comes three months after cangrelor was given marketing authorisation across the EU for the treatment of patients with acute coronary syndrome and vascular surgical procedures.

The European Medicines Agency concluded that cangrelor’s benefits outweighed its risks: “Although the incidence of bleeding was higher for Kengrexal than for clopidogrel, this was expected given the greater effectiveness of the medicine, and was offset by the fact that the activity of Kengrexal wore off quickly once the infusion was stopped.” 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068822

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.